Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Top Cited Papers
Open Access
- 30 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 54 (7) , 922-928
- https://doi.org/10.1093/cid/cir970
Abstract
(See the Editorial Commentary by Li et al, on pages 929–30.)Keywords
This publication has 29 references indexed in Scilit:
- Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older AdultsJournal of the American Geriatrics Society, 2010
- Zoster Vaccine: Current Status and Future ProspectsClinical Infectious Diseases, 2010
- The impact of herpes zoster and post-herpetic neuralgia on quality-of-lifeBMC Medicine, 2010
- Influence of Age and Nature of Primary Infection on Varicella‐Zoster Virus–Specific Cell‐Mediated Immune ResponsesThe Journal of Infectious Diseases, 2010
- Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health PlansPharmacoEconomics, 2009
- Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or OlderClinical and Vaccine Immunology, 2009
- A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of ZostavaxClinical and Vaccine Immunology, 2008
- Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic ReviewPLoS Medicine, 2005
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Exact power and sample size for vaccine efficacy studiesCommunications in Statistics - Theory and Methods, 1998